Biohaven
NEWS
It was a busy week for clinical trial updates. Here’s a look.
It was a busy week for clinical trial updates. Here’s a look.
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
It was a very busy week for clinical trial news. Here’s a look.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Biohaven Pharmaceutical announced positive topline data from its Phase III trial of oral rimegepant (Nurtec) for preventing migraine headaches in both episodic and chronic migraine patients.
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
The company said the decision to advance the CGRP receptor antagonist into late-stage studies followed a successful end-of-phase meeting with the U.S. Food and Drug Administration.
JOBS
IN THE PRESS